Clinical trial · Observational
Cancer Panel From Blood of Lung Cancer Patients
Clinical Validity of Oncogenic Driver Genes Detected From Circulating Tumor DNA in Blood of Lung Cancer Patients
NCT03235765CI-TRIAL-00036669CAPABLEunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer Metastatic | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MACROGEN Pan Cancer Panel (Tier 2) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cohort A
- description
- Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
- interventionNames
- Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)
- label
- Cohort B
- description
- Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
- interventionNames
- Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)
Primary outcomes (1)
- measure
- Concordance rate
- timeFrame
- an average of one year
- description
- Concordance rate of genomic change between tumor tissue (FFPE) and ctDNA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures, sampling, and analyses * Pathologically confirmed non-small cell lung cancer * Male or female, aged at least 20 years * Matches one of two criteria : 1. Cohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy 2. Cohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent. Exclusion Criteria: * Any concurrent and/or other active malignancy that has required treatment within 3 years * Patients with mixed small cell histology * Life expectancy less than 3 months * Insufficient tissue for NGS test
References
Publications (0)
Data not yet available
No reference posted for this study.